{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T08:55:27Z","timestamp":1790931327309,"version":"4.1.0"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T00:00:00Z","timestamp":1782950400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T00:00:00Z","timestamp":1782950400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Nucl Med Mol Imaging"],"published-print":{"date-parts":[[2026,10]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>To determine the degree of tumor necrosis on pathology and clinical outcomes among intrahepatic cholangiocarcinoma (iCCA) patients who were treated with transarterial radioembolization (TARE) and the bridge or downstaged to surgery.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      A single center retrospective review was performed to include consecutive patients who underwent TARE using glass microspheres and then subsequently underwent surgical resection or transplant. Baseline characteristics, dosimetry, radiologic response, histological tumor necrosis, and overall survival were evaluated. A total of 20 patients (F: M\u2009=\u200914:6; age: 57.3\u2009\u00b1\u200910.8 years) underwent TARE and then received resection (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200915) or living-donor liver transplant (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u20095). A total of 23 selective TARE (two segments or less) were delivered, with a mean dose 301.7\u2009\u00b1\u2009177.5, whereas 18 lobar (left or right hepatic artery) doses were delivered, with a mean dose of 150.3\u2009\u00b1\u200944.1\u00a0Gy. Concurrent systemic therapy was administered in 15 patients.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      The mean time from the initial TARE to surgery was 7.1\u2009\u00b1\u20099.2 months. On pathology, complete tumor necrosis, &gt;\u200990% necrosis, and extensive tumor necrosis (&gt;\u200950%) were achieved in 1 (5.0%), 13 (65.0%), and 18 (90.0%) patients, respectively. The median survival time (MST) calculated from the time of surgery was 40.2 (95%CI: 15.3-not reached) months, with a 1-yr, 3-yr, and 5-yr OS of 88.2% (95CI: 60.6\u201396.9%), 57.8% (95%CI: 31.1\u201377.3%), and 19.8% (95%CI: 1.5\u201353.5%). From the time of initial TARE, the MST was 41.4 (95%CI:22.9-not reached) month, with a 1-yr, 3-yr, and 5-yr OS of 100%, 69.9% (95%CI: 42.0-86.3%), and 30.9% (95%CI: 9.1\u201356.3%). Whether the patient received concomitant systemic treatment was associated with extensive tumor necrosis on pathology (Odds Ratio: 16.0, 95%CI: 1.27-200.92,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.032).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Based on tumor explant data, TARE can result in substantial tumor necrosis in the treatment of iCCA, although complete necrosis is uncommon. The addition of systemic therapy appears to be associated with a higher likelihood of achieving extensive tumor necrosis.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00259-026-07996-y","type":"journal-article","created":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T06:48:37Z","timestamp":1782974917000},"page":"6920-6929","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Intrahepatic cholangiocarcinoma treated with glass yttrium-90 radioembolization: A histopathologic study"],"prefix":"10.1007","volume":"53","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9774-9226","authenticated-orcid":false,"given":"Qian","family":"Yu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peizi","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satvik","family":"Jain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdul","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Steiner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chih-Yi","family":"Liao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Franses","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anjana","family":"Pillai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Fung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J Michael","family":"Millis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rakesh","family":"Navuluri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven","family":"Zangan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"Funaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Hart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Osman","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thuong","family":"Van Ha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,2]]},"reference":[{"issue":"4","key":"7996_CR1","doi-asserted-by":"publisher","first-page":"1777","DOI":"10.21037\/jgo-24-165","volume":"15","author":"Y Wang","year":"2024","unstructured":"Wang Y, Alsaraf Y, Bandaru SS, et al. Epidemiology, survival and new treatment modalities for intrahepatic cholangiocarcinoma. J Gastrointest Oncol. 2024;15(4):1777\u201388.","journal-title":"J Gastrointest Oncol"},{"issue":"5","key":"7996_CR2","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1159\/000516880","volume":"10","author":"Q Yu","year":"2021","unstructured":"Yu Q, Liu C, Pillai A, Ahmed O. Twenty years of radiation therapy of unresectable intrahepatic cholangiocarinoma: internal or external? A systematic review and meta-analysis. Liver Cancer. 2021;10(5):433\u201350.","journal-title":"Liver Cancer"},{"issue":"11","key":"7996_CR3","doi-asserted-by":"publisher","first-page":"1970","DOI":"10.1016\/j.jvir.2023.07.028","volume":"34","author":"Q Yu","year":"2023","unstructured":"Yu Q, Patel M, Kwak D, et al. Segmental yttrium-90 radioembolization using glass microspheres greater than 400 gray for the treatment of intrahepatic cholangiocarcinoma: a preliminary experience. J Vasc Interv Radiol. 2023;34(11):1970\u20136. e1.","journal-title":"J Vasc Interv Radiol"},{"issue":"20","key":"7996_CR4","doi-asserted-by":"publisher","first-page":"2075","DOI":"10.18632\/oncotarget.28060","volume":"12","author":"R Paz-Fumagalli","year":"2021","unstructured":"Paz-Fumagalli R, Core J, Padula C, et al. Safety and initial efficacy of ablative radioembolization for the treatment of unresectable intrahepatic cholangiocarcinoma. Oncotarget. 2021;12(20):2075.","journal-title":"Oncotarget"},{"issue":"4","key":"7996_CR5","doi-asserted-by":"publisher","first-page":"2374","DOI":"10.1007\/s00330-023-10203-3","volume":"34","author":"Q Yu","year":"2024","unstructured":"Yu Q, Ungchusri E, Pillai A, et al. Selective internal radiation therapy using yttrium-90 microspheres for treatment of localized and locally advanced intrahepatic cholangiocarcinoma. Eur Radiol. 2024;34(4):2374\u201383.","journal-title":"Eur Radiol"},{"issue":"11","key":"7996_CR6","doi-asserted-by":"publisher","first-page":"1560","DOI":"10.1016\/j.jvir.2021.08.009","volume":"32","author":"A Sarwar","year":"2021","unstructured":"Sarwar A, Ali A, Ljuboja D, et al. Neoadjuvant yttrium-90 transarterial radioembolization with resin microspheres prescribed using the medical internal radiation dose model for intrahepatic cholangiocarcinoma. J Vasc Interv Radiol. 2021;32(11):1560\u20138.","journal-title":"J Vasc Interv Radiol"},{"issue":"7","key":"7996_CR7","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1016\/j.jvir.2024.03.005","volume":"35","author":"Q Yu","year":"2024","unstructured":"Yu Q, Wang Y, Ungchusri E, et al. Modified radiation lobectomy strategy of radioembolization for Right-Sided unresectable primary liver tumors. J Vasc Interv Radiol. 2024;35(7):989\u201397. e2.","journal-title":"J Vasc Interv Radiol"},{"issue":"4","key":"7996_CR8","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1016\/j.jvir.2024.12.016","volume":"36","author":"AN Gupta","year":"2025","unstructured":"Gupta AN, Serhal M, Gordon AC, et al. Radiation segmentectomy and modified radiation lobectomy for unresectable early-stage intrahepatic cholangiocarcinoma. J Vasc Interv Radiol. 2025;36(4):650\u20139.","journal-title":"J Vasc Interv Radiol"},{"issue":"10","key":"7996_CR9","doi-asserted-by":"publisher","first-page":"3820","DOI":"10.1007\/s00259-025-07229-8","volume":"52","author":"M Lam","year":"2025","unstructured":"Lam M, Salem R, Toskich B, et al. Clinical and dosimetric considerations for yttrium-90 glass microspheres radioembolization of intrahepatic cholangiocarcinoma, metastatic colorectal carcinoma, and metastatic neuroendocrine carcinoma: recommendations from an international multidisciplinary working group. Eur J Nucl Med Mol Imaging. 2025;52(10):3820\u201332.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"4","key":"7996_CR10","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1016\/j.jvir.2022.12.017","volume":"34","author":"O Ahmed","year":"2023","unstructured":"Ahmed O, Yu Q, Patel M, et al. Yttrium-90 radioembolization and concomitant systemic gemcitabine, cisplatin, and capecitabine as the first-line therapy for locally advanced intrahepatic cholangiocarcinoma. J Vasc Interv Radiol. 2023;34(4):702\u20139.","journal-title":"J Vasc Interv Radiol"},{"issue":"1","key":"7996_CR11","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1001\/jamaoncol.2019.3702","volume":"6","author":"J Edeline","year":"2020","unstructured":"Edeline J, Touchefeu Y, Guiu B, et al. Radioembolization plus chemotherapy for first-line treatment of locally advanced intrahepatic cholangiocarcinoma: a phase 2 clinical trial. JAMA Oncol. 2020;6(1):51\u20139.","journal-title":"JAMA Oncol"},{"issue":"5","key":"7996_CR12","doi-asserted-by":"publisher","first-page":"2202","DOI":"10.21037\/jgo-23-210","volume":"14","author":"S Young","year":"2023","unstructured":"Young S, Torkian P, Flanagan S, D\u2019Souza D, Sanghvi T, Golzarian J. Intrahepatic cholangiocarcinoma: a dose threshold evaluation in those undergoing transarterial radioembolization. J Gastrointest Oncol. 2023;14(5):2202.","journal-title":"J Gastrointest Oncol"},{"issue":"9","key":"7996_CR13","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1016\/j.jvir.2023.05.026","volume":"34","author":"B Kis","year":"2023","unstructured":"Kis B, Shridhar R, Mhaskar R, et al. Radioembolization with yttrium-90 glass microspheres as a first-line treatment for unresectable intrahepatic cholangiocarcinoma\u2014a prospective feasibility study. J Vasc Interv Radiol. 2023;34(9):1547\u201355.","journal-title":"J Vasc Interv Radiol"},{"issue":"4","key":"7996_CR14","doi-asserted-by":"publisher","first-page":"2455","DOI":"10.1007\/s00259-025-07641-0","volume":"53","author":"MM Tahir","year":"2026","unstructured":"Tahir MM, Nasser IA, Odeh M, et al. Histopathologic analysis of intrahepatic cholangiocarcinoma treated with transarterial radioembolization using Yttrium-90 resin microspheres. Eur J Nucl Med Mol Imaging. 2026;53(4):2455\u201365.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"1154","key":"7996_CR15","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1093\/bjr\/tqad056","volume":"97","author":"DH Kwak","year":"2024","unstructured":"Kwak DH, Lionberg A, Patel M, et al. Quantitative differences in volumetric calculations for radiation dosimetry in segmental Y90 treatment planning using hybrid angiography-CT compared with anatomic segmentation. Br J Radiol. 2024;97(1154):353\u201362.","journal-title":"Br J Radiol"},{"issue":"2","key":"7996_CR16","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1007\/s00259-020-04976-8","volume":"48","author":"A Gabr","year":"2021","unstructured":"Gabr A, Riaz A, Johnson GE, et al. Correlation of Y90-absorbed radiation dose to pathological necrosis in hepatocellular carcinoma: confirmatory multicenter analysis in 45 explants. Eur J Nucl Med Mol Imaging. 2021;48(2):580\u20133.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7996_CR17","doi-asserted-by":"crossref","unstructured":"Entezari P, Gabr A, Kennedy K, Salem R, Lewandowski RJ. Radiation lobectomy: an overview of concept and applications, technical considerations, outcomes. Thieme Medical Publishers, Inc.; 2021. pp. 419\u201324.","DOI":"10.1055\/s-0041-1735530"},{"issue":"8","key":"7996_CR18","doi-asserted-by":"publisher","first-page":"EVIDoa2200015","DOI":"10.1056\/EVIDoa2200015","volume":"1","author":"D-Y Oh","year":"2022","unstructured":"Oh D-Y, Ruth He A, Qin S, et al. Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer. NEJM Evid. 2022;1(8):EVIDoa2200015.","journal-title":"NEJM Evid"},{"issue":"9","key":"7996_CR19","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1016\/S2468-1253(22)00091-7","volume":"7","author":"E Kim","year":"2022","unstructured":"Kim E, Sher A, Abboud G, et al. Radiation segmentectomy for curative intent of unresectable very early to early stage hepatocellular carcinoma (RASER): a single-centre, single-arm study. Lancet Gastroenterol Hepatol. 2022;7(9):843\u201350.","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"12","key":"7996_CR20","doi-asserted-by":"publisher","first-page":"3744","DOI":"10.1007\/s00259-024-06813-8","volume":"51","author":"KT Pianka","year":"2024","unstructured":"Pianka KT, Barahman M, Minocha J, et al. Voxel-based tumor dose correlates to complete pathologic necrosis after transarterial radioembolization for hepatocellular carcinoma. Eur J Nucl Med Mol Imaging. 2024;51(12):3744\u201352.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"4","key":"7996_CR21","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1016\/j.jvir.2020.12.019","volume":"32","author":"B Toskich","year":"2021","unstructured":"Toskich B, Vidal LL, Olson MT, et al. Pathologic response of hepatocellular carcinoma treated with yttrium-90 glass microsphere radiation segmentectomy prior to liver transplantation: a validation study. J Vasc Interv Radiol. 2021;32(4):518\u201326. e1.","journal-title":"J Vasc Interv Radiol"},{"issue":"4","key":"7996_CR22","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1002\/hep.22747","volume":"49","author":"A Riaz","year":"2009","unstructured":"Riaz A, Kulik L, Lewandowski RJ, et al. Radiologic\u2013pathologic correlation of hepatocellular carcinoma treated with internal radiation using yttrium-90 microspheres. Hepatology. 2009;49(4):1185\u201393.","journal-title":"Hepatology"},{"key":"7996_CR23","doi-asserted-by":"crossref","unstructured":"Lawrence TS, Blackstock AW, McGinn C. The mechanism of action of radiosensitization of conventional chemotherapeutic agents. Elsevier; 2003. pp. 13\u201321.","DOI":"10.1053\/srao.2003.50002"}],"container-title":["European Journal of Nuclear Medicine and Molecular Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-026-07996-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00259-026-07996-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-026-07996-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T08:31:46Z","timestamp":1790929906000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00259-026-07996-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,2]]},"references-count":23,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["7996"],"URL":"https:\/\/doi.org\/10.1007\/s00259-026-07996-y","relation":{},"ISSN":["1619-7070","1619-7089"],"issn-type":[{"value":"1619-7070","type":"print"},{"value":"1619-7089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,2]]},"assertion":[{"value":"15 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study was performed in line with the principles of the Declaration of Helsinki. Approval was granted by the Ethics Committee of University of Chicago.","order":1,"name":"Ethics","label":"Ethics approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"OA reported receiving personal fees from Argon Medical, Penumbra, Medtronic, Johnson & Johnson, and Boston Scientific and grants from Canon Medical, outside the submitted work. AP is on the medical advisory board for Eisai Inc., Exelixis, Genentech, AstraZeneca, and Replimune. JF receives consulting fees from Eisai, Foundation Medicine, Genentech, and Guardant Health, as well as institutional research support from Abbvie, Alnylam, Genentech, Iterion Therapeutics, and Omega Therapeutics.The remaining authors have no conflicts to report.","order":2,"name":"Ethics","label":"Financial disclosure","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This is an observational study. Informed consent was waived by the IRB of University of Chicago.","order":3,"name":"Ethics","label":"Consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This is an observational study. Informed consent was waived by the IRB of University of Chicago.","order":4,"name":"Ethics","label":"Consent to publish","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"None.","order":5,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}}]}}